Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 24;4(2):193–207. doi: 10.1002/hep4.1453

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Icosabutate improves NASH and liver fibrosis. Histological photomicrographs of liver cross sections stained with H&E or sirius red (A) and quantitative analysis (B‐J) of NASH and liver fibrosis in APOE*3Leiden.CETP mice fed a high‐fat/cholesterol diet and left untreated (control) or treated with icosabutate or rosiglitazone for 20 weeks. Macrovesicular steatosis (B), microvesicular steatosis (C) and hepatocellular hypertrophy (D) as percentage of total liver area, intrahepatic triglycerides (E), free cholesterol (F) and cholesterol esters (G), inflammatory foci per millimeters‐squared microscopic field (H), and fibrosis as percentage of total liver area (I) or as hepatic collagen content (J) were analyzed. Values represent mean ± SEM for 12 mice per group (*p < 0.05, **p < 0.01, ***p < 0.001 versus control).